Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296712 · ClinicalTrials.gov registry record · Phase 4
Are Two Antidepressants a Good Initial Treatment for Depression?
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT00296712: Completed Phase 4 study, sponsored by New York State Psychiatric Institute.
NCT00296712 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 55 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00296712, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
Relatively drug naive patients will receive two antidepressant medications as initial treatment.
Interventions
- DRUG escitalopram + bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-07 |
| Phase | Phase 4 |
What the finished NCT00296712 record still lists
NCT00296712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which escitalopram + bupropion is the first listed.
NCT00296712 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00296712 about?
NCT00296712 is a clinical study titled "Are Two Antidepressants a Good Initial Treatment for Depression?". Relatively drug naive patients will receive two antidepressant medications as initial treatment.
What is the current status of trial NCT00296712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2005-02. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00296712?
The interventions under investigation include: escitalopram + bupropion (DRUG).
Who is sponsoring clinical trial NCT00296712?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00296712's enrollment target sits among peer trials
55 1218th of 2000 higher than 778 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia